Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment

Ganipineni, Lakshmi Pallavi; Danhier, Fabienne; Préat, Véronique

doi:10.1016/j.jconrel.2018.05.008

Cited by 180 publications

(101 citation statements)

References 151 publications

Supporting

Mentioning

100

Contrasting

Order By: Relevance

“…Second, the blood–brain barrier (BBB) is a physical transport barrier that strictly regulates the import and export of substances into the brain, such that transport across the BBB of nearly 98% therapeutics is inhibited . Even if the BBB is successfully traversed, how to precisely transport the therapeutic to the diseased area of the brain and then control release for high‐efficiency onsite GBM therapy are other difficult technical problems that represent developmental bottlenecks …”

mentioning

confidence: 99%

Effective and Targeted Human Orthotopic Glioblastoma Xenograft Therapy via a Multifunctional Biomimetic Nanomedicine

et al. 2018

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is a fatal central nervous system tumor without effective treatment. Chemotherapeutic agents are mainstays in the treatment of glioblastoma. However, the effectiveness of these is seriously hindered by poor blood–brain‐barrier (BBB) penetrance and tumor targeting, together with short biological half‐life. Improved chemotherapy is thus urgently needed for GBM. Multifunctional nanoparticle delivery systems offer much promise in overcoming current limitations. Accordingly, a multifunctional biomimetic nanomedicine is developed by functionalizing the surface of red blood cell membranes (RBCms) with angiopep‐2 and loading pH‐sensitive nanoparticles (polymer, doxorubicin (Dox), and lexiscan (Lex)) using the functionalized cell membrane to generate the novel nanomedicine, Ang‐RBCm@NM‐(Dox/Lex). The studies toward orthotopic U87MG human glioblastoma tumor‐bearing nude mice show that the Ang‐RBCm@NM‐(Dox/Lex) nanomedicine has much improved blood circulation time, superb BBB penetration, superior tumor accumulation and retention. Moreover, effective suppression of tumor growth and significantly improved medium survival time are also observed after Ang‐RBCm@NM‐(Dox/Lex) treatment. The results show that this biomimetic nanoplatform can serve as a flexible and powerful system for GBM treatment which can be readily adapted for the treatment of other central nervous system (CNS) disorders.

show abstract

mentioning

confidence: 99%

Effective and Targeted Human Orthotopic Glioblastoma Xenograft Therapy via a Multifunctional Biomimetic Nanomedicine

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Nanomedicine‐based glioma therapy strategies have limited outcomes in clinical trials. Recent clinical trials of nanomedicine for treating GBM include nanoliposomal CPT‐11 (camptothecin‐11/irinotecan) (NCT00734682), liposomal doxorubicin (MYOCET) (NCT02861222), PEGylated liposomal doxorubicin (NCT00944801), rhenium nanoliposome (NCT01906385), small spherical AuNP (NCT03020017), AGuIX® particles + radiation therapy (NCT02820454), and EnGeneIC delivery vehicle (EDV, nanocellular doxorubicin targets EGFR through Vectibix) (NCT02766699) (Ganipineni, Danhier, & Préat, ).…”

Section: Clinical Translation Of Nanoparticles In Gliomamentioning

confidence: 99%

Immunoengineering in glioblastoma imaging and therapy

Zanganeh

Georgala

Corbo

et al. 2019

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Patients diagnosed with glioblastoma have poor prognosis. Conventional treatment strategies such as surgery, chemotherapy, and radiation therapy demonstrated limited clinical success and have considerable side effects on healthy tissues. A central challenge in treating brain tumors is the poor permeability of the blood–brain barrier (BBB) to therapeutics. Recently, various methods based on immunotherapy and nanotechnology have demonstrated potential in addressing these obstacles by enabling precise targeting of brain tumors to minimize adverse effects, while increasing targeted drug delivery across the BBB. In addition to treating the tumors, these approaches may be used in conjunction with imaging modalities, such as magnetic resonance imaging and positron emission tomography to enhance the prognosis procedures. This review aims to provide mechanistic understanding of immune system regulation in the central nervous system and the benefits of nanoparticles in the prognosis of brain tumors. This article is characterized under: Diagnostic Tools > in vivo Nanodiagnostics and Imaging Nanotechnology Approaches to Biology > Cells at the Nanoscale Nanotechnology Approaches to Biology > Nanoscale Systems in Biology

show abstract

“…Also, different delivery strategies have been developed, as viral delivery vehicles, nonviral delivery vehicles and multifunctional delivery systems. [ 149,150 ] Although nanoparticles are able to cross the BBB, active targeting to tumor tissue still needs to be improved. Polymeric nanoparticles and CED, polymeric micelles and CED, and liposomal nanoparticles and active tumor targeting are plausible therapeutic strategies.…”

Section: Clinical Management Of Glioblastoma: New Diagnosis Opportunimentioning

confidence: 99%

Advances in the Knowledge of the Molecular Biology of Glioblastoma and Its Impact in Patient Diagnosis, Stratification, and Treatment

2020

View full text Add to dashboard Cite

Gliomas are the most common primary brain tumors in adults. They arise in the glial tissue and primarily occur in the brain. Low‐grade tumors of World Health Organization (WHO) grade II tend to progress to high‐grade gliomas of WHO grade III and, eventually, glioblastoma of WHO grade IV, which is the most common and deadly glioma, with a median survival of 12–15 months after final diagnosis. Knowledge of the molecular biology and genetics of glioblastoma has increased significantly in the past few years, giving rise to classification methods that can help in management and stratification of glioblastoma patients. However, glioblastoma remains an incurable disease. Glioblastoma cells have acquired genetic and metabolic adaptations in order to sustain tumor growth and progression, including changes in energetic metabolism, invasive capacity, migration, and angiogenesis, that make it very difficult to find suitable therapeutic targets and to develop effective drugs. The current standard of care for glioblastoma patients is surgery followed by radiotherapy plus concomitant and adjuvant chemotherapy with temozolomide. Although progress in glioblastoma therapies in recent years has been more limited than in other tumors, numerous drugs and targets are being proposed and many clinical trials are underway to develop effective subtype‐specific treatments.

show abstract

Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment

Cited by 180 publications

References 151 publications

Effective and Targeted Human Orthotopic Glioblastoma Xenograft Therapy via a Multifunctional Biomimetic Nanomedicine

Effective and Targeted Human Orthotopic Glioblastoma Xenograft Therapy via a Multifunctional Biomimetic Nanomedicine

Immunoengineering in glioblastoma imaging and therapy

Advances in the Knowledge of the Molecular Biology of Glioblastoma and Its Impact in Patient Diagnosis, Stratification, and Treatment

Contact Info

Product

Resources

About